{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:11:01Z","timestamp":1793232661249,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41591-026-04640-y","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:03:37Z","timestamp":1789031017000},"page":"3633-3643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Curmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3953-8241","authenticated-orcid":false,"given":"Aya","family":"Ajrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"De Rycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-2923","authenticated-orcid":false,"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-944X","authenticated-orcid":false,"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"4640_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","volume":"61","author":"A Geraud","year":"2021","unstructured":"Geraud, A. et al. Clinical pharmacology and interplay of immune checkpoint agents: a yin\u2013yang balance. Annu. Rev. Pharmacol. Toxicol. 61, 85\u2013112 (2021).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"4640_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24112-w","volume":"12","author":"R Banchereau","year":"2021","unstructured":"Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).","journal-title":"Nat. Commun."},{"key":"4640_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann. Oncol. 35, 508\u2013522 (2024).","journal-title":"Ann. Oncol."},{"key":"4640_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","volume":"19","author":"A Fendler","year":"2022","unstructured":"Fendler, A. et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 19, 385\u2013401 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4640_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat. Med. 25, 1243\u20131250 (2019).","journal-title":"Nat. Med."},{"key":"4640_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","volume":"596","author":"PS Arunachalam","year":"2021","unstructured":"Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410\u2013416 (2021).","journal-title":"Nature"},{"key":"4640_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lore, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"4640_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647, 488\u2013497 (2025).","journal-title":"Nature"},{"key":"4640_CR9","doi-asserted-by":"publisher","first-page":"e103690","DOI":"10.7554\/eLife.103690","volume":"14","author":"H Chemaitelly","year":"2025","unstructured":"Chemaitelly, H. et al. Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar. eLife 14, e103690 (2025).","journal-title":"eLife"},{"key":"4640_CR10","doi-asserted-by":"crossref","unstructured":"Jee, J. et al. Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival in a Pandemic (Cold Spring Harbor Laboratory, 2025).","DOI":"10.1101\/2025.11.21.25340753"},{"key":"4640_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006246","volume":"11","author":"JI Ruiz","year":"2023","unstructured":"Ruiz, J. I., Lopez-Olivo, M. A., Geng, Y. & Suarez-Almazor, M. E. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. J. Immunother. Cancer 11, e006246 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"4640_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin, B., Agbarya, A., Safadi, E., Padova, H. & Wolf, I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 22, 581\u2013583 (2021).","journal-title":"Lancet Oncol."},{"key":"4640_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004157","volume":"10","author":"Q Mei","year":"2022","unstructured":"Mei, Q. et al. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study. J. Immunother. Cancer 10, e004157 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4640_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","volume":"79","author":"O Maillard","year":"2024","unstructured":"Maillard, O. et al. Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase. Therapie 79, 659\u2013669 (2024).","journal-title":"Therapie"},{"key":"4640_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","volume":"47","author":"JE Salem","year":"2025","unstructured":"Salem, J. E. et al. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur. Heart J. 47, 1014\u20131030 (2025).","journal-title":"Eur. Heart J."},{"key":"4640_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101484","volume":"59","author":"H Jourdain","year":"2025","unstructured":"Jourdain, H. et al. PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study. Lancet Reg. Health Eur. 59, 101484 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"4640_CR17","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","volume":"360","author":"MA Hernan","year":"2018","unstructured":"Hernan, M. A. How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ 360, k182 (2018).","journal-title":"BMJ"},{"key":"4640_CR18","doi-asserted-by":"publisher","first-page":"e2546822","DOI":"10.1001\/jamanetworkopen.2025.46822","volume":"8","author":"L Semenzato","year":"2025","unstructured":"Semenzato, L. et al. COVID-19 mRNA vaccination and 4-year all-cause mortality among adults aged 18 to 59 years in France. JAMA Netw. Open 8, e2546822 (2025).","journal-title":"JAMA Netw. Open"},{"key":"4640_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","volume":"7","author":"RB Parikh","year":"2021","unstructured":"Parikh, R. B. et al. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. JAMA Oncol. 7, 1843 (2021).","journal-title":"JAMA Oncol."},{"key":"4640_CR20","volume":"4","author":"DE Meyers","year":"2023","unstructured":"Meyers, D. E. et al. Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors. JTO Clin. Res. Rep. 4, 100482 (2023).","journal-title":"JTO Clin. Res. Rep."},{"key":"4640_CR21","doi-asserted-by":"publisher","first-page":"e25115","DOI":"10.1097\/MD.0000000000025115","volume":"100","author":"A Kapoor","year":"2021","unstructured":"Kapoor, A. et al. Immune checkpoint inhibitors in patients with solid tumors and poor performance status. Medicine 100, e25115 (2021).","journal-title":"Medicine"},{"key":"4640_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"4640_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hernan","year":"2016","unstructured":"Hernan, M. A., Sauer, B. C., Hernandez-Diaz, S., Platt, R. & Shrier, I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J. Clin. Epidemiol. 79, 70\u201375 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"4640_CR24","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","volume":"49","author":"C Maringe","year":"2020","unstructured":"Maringe, C. et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int. J. Epidemiol. 49, 1719\u20131729 (2020).","journal-title":"Int. J. Epidemiol."},{"key":"4640_CR25","doi-asserted-by":"crossref","unstructured":"Constantinou, P., Jean, C., Canoui-Poitrine, F. & Ferrat, E. Non-COVID-19 mortality among older people or with chronic conditions during year 2020 in France: a nationwide cohort study. BMC Public Health 25, (2025).","DOI":"10.1186\/s12889-025-23622-2"},{"key":"4640_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jflm.2016.12.004","volume":"57","author":"G Rey","year":"2018","unstructured":"Rey, G., Bounebache, K. & Rondet, C. Causes of deaths data, linkages and big data perspectives. J. Forensic Leg. Med. 57, 37\u201340 (2018).","journal-title":"J. Forensic Leg. Med."},{"key":"4640_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","volume":"406","author":"GBDC Collaborators","year":"2025","unstructured":"Collaborators, G. B. D. C. The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565\u20131586 (2025).","journal-title":"Lancet"},{"key":"4640_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey, G., Jougla, E., Fouillet, A. & Hemon, D. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 9, 33 (2009).","journal-title":"BMC Public Health"},{"key":"4640_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100970","volume":"43","author":"A Rousseau","year":"2024","unstructured":"Rousseau, A. et al. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. Lancet Reg. Health Eur. 43, 100970 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"4640_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin, P. C., Lee, D. S. & Fine, J. P. Introduction to the analysis of survival data in the presence of competing risks. Circulation 133, 601\u2013609 (2016).","journal-title":"Circulation"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04640-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:31:16Z","timestamp":1792038676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4640"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04640-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}